Evofem Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six months ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(3,458) | $(10,912) |
| Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities: | ||
| Loss on issuance of financial instruments | 3,300 | 111 |
| Change in fair value of financial instruments | (4,127) | (1,539) |
| Gain on debt extinguishment | (1,120) | - |
| Stock-based compensation | 456 | 685 |
| Depreciation | 19 | 418 |
| Noncash interest expense | 1,109 | 1,134 |
| Noncash right-of-use asset amortization | 82 | 1,208 |
| Net gain on lease termination | - | (459) |
| Net loss on disposal of property and equipment | 11 | 1,858 |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 1,121 | (4,072) |
| Inventories | 637 | 1,705 |
| Prepaid and other assets | 349 | 2,435 |
| Accounts payable | (987) | 2,167 |
| Accrued expenses and other liabilities | 1,000 | 840 |
| Accrued compensation | 671 | (625) |
| Operating lease liabilities | (81) | (1,388) |
| Net cash and restricted cash used in operating activities | (1,018) | (6,434) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (14) | (4) |
| Net cash and restricted cash used in investing activities | (14) | (4) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock - exercise of warrants | - | 160 |
| Borrowings under term notes | - | 2,138 |
| Proceeds from reinstatement of Merger Agreement – Related Party | 1,000 | - |
| Borrowings under short-term debt | 397 | - |
| Payments under notes carried at fair value | (253) | - |
| Net cash and restricted cash provided by financing activities | 1,144 | 2,298 |
| Net change in cash, cash equivalents and restricted cash | 112 | (4,140) |
| Cash, cash equivalents and restricted cash, beginning of period | 580 | 4,776 |
| Cash, cash equivalents and restricted cash, end of period | $692 | $636 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Issuance of common stock upon exercise of purchase rights | 157 | 186 |
| Series E-1 shares deemed dividends | 94 | - |
| Issuance of common stock upon conversion of notes | 51 | - |
| Issuance of common stock upon exercise of warrants | 15 | - |
| Purchases of property and equipment included in accounts payable and accrued expenses | 78 | - |
Table of Contents
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.